Scientific Method Rigour Tracks Readiness as High-Readiness Rates Rise From 7.9% to 51.7% While 49.7% of 3,581 Research Records State None of Eight Rigour Signals

InnoDexis has published its latest Innovation Intelligence Report covering scientific method and rigour, analyzing all 3,581 retained research records and all 4,840 corporate records across 12 study-design classes and 8 recountable rigour signals during the 1–29 September 2026 observation window. The report reveals that readiness rises with stated rigour and half the stream states none: 1,780 research records, 49.7 percent, state none of the eight signals, and 79.1 percent of corporate records state no evidence beyond the claim itself. Randomised trials lead at 3.00 signals on average.

Key Findings

Rigour is rare. Half the research stream, 1,780 records, states none of the eight rigour signals and only 58 records, 1.6 percent, state four or more, while statistical inference appears in 2.6 percent of records, randomisation in 3.3 percent, external validation or replication in 1.9 percent and blinding in 0.9 percent.

Readiness rises with stated rigour. Research records stating no signal are rated High for commercial readiness 7.9 percent of the time and those stating four or more 51.7 percent, and the evidence hierarchy holds by design: randomised trials carry 49.1 percent High readiness, meta-analyses 30.0 percent, cohorts and registries 22.0 percent, computational work 7.6 percent and animal studies 0.4 percent.

Computational and AI work is the largest and least validated class. It holds 751 records, 21.0 percent of the stream, and states external validation in 3 percent, though Caris Life Sciences with ECOG-ACRIN reported an AI model outperforming a standard genomic test across 4,429 patients.

Corporate claims are mostly unevidenced. Of 4,840 corporate records, 3,829, 79.1 percent, state no evidence and 754 cite only customer counts, while clinical-trial evidence carries 24.1 percent High momentum and analyst-firm evidence 42.1 percent, against 11.3 percent for records with none.

Peer review alone does not lift momentum. Records citing a peer-reviewed publication score 5.69 against 4.98 but carry only 10.6 percent High momentum, and research gaps name replication or validation in 499 records against 58 for sample size.

Strategic Insight and Trend Analysis

The defining structural finding is that evidence and readiness travel together. Human evidence with a comparator is closest to use, while mechanistic and preclinical work is furthest from it, however strong the science. Randomised trials, the most rigorous class at 3.00 signals on average, carry 49.1 percent High readiness. The rigour index measures what record summaries state, not what studies did, so the absence of a signal is not proof of absent rigour, and the analyst readiness rating and the text-count index agree strongly enough that either can serve as a first filter.

Validation is the stream’s weakest signal and its clearest commercial gap. Research gaps name replication or validation in 499 records, long-term follow-up in 759, human translation in 397 and generalisability in 224, which means the problem is less often too few subjects than too few independent tests, and the reporting positions of blinding and preregistration remain almost unclaimed.

Basic science publishes while clinical science presents. Animal studies name a journal in 46 percent of records and cell and molecular studies in 39 percent, against 8 percent of cohort studies, and congress records average 1.71 rigour signals against 0.71 for other sources, because Phase 3 and registry presentations report statistics. Institutions differ sharply, with Mass General Brigham at 2.00 signals, Karolinska Institutet at 1.90 and the University of Liverpool at 1.80.

Global and Industry Implications

For corporates and R&D teams, scouting should require at least two stated signals, since High readiness is 18.1 percent at two signals against 7.9 percent at none, and licensors should require external validation before licensing AI models. Corporate announcements that state clinical or third-party evidence carry 24.1 and 42.1 percent High momentum against 11.3 percent without, and sponsoring second-site replication of single-centre trials at Liverpool, Heidelberg and Mayo Clinic is the named route.

For investors and capital allocators, rigour is an investable filter, and validation services for AI are a business in their own right. Due diligence should count the eight signals, ask for the held-out test, and distinguish a congress abstract from a peer-reviewed paper, favouring formations with comparator evidence such as ART-EMIS Hamburg and HaemAnalytica.

For policymakers and national innovation bodies, funding replication and long-term follow-up would raise the readiness of a large share of existing research at low cost. Registry linkage on the Nordic model, reporting standards for AI validation and preregistration incentives are the named levers, and replication and long-term follow-up are what research lacks and what services can sell.

InnoDexis Statement

“Readiness rises with stated rigour and half the stream states none — a result with a comparator, a second cohort and a stated statistic is licensable, and one without is a lead,” noted InnoDexis in its latest intelligence report.

Conclusion

Because the index measures what summaries state rather than what studies did, and one month supports no trend, the findings are cross-sectional. The signals to watch are whether the share of computational records stating external validation rises above 10 percent, whether named replication programmes appear in research records, whether academic assets are registered as randomised trials, and whether mean rigour signals rise above 1.0. Each is a specific, observable test. The complete Scientific Method & Rigour Report September 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.